Cancer Chemotherapy and Pharmacology

, Volume 8, Issue 1, pp 105–111 | Cite as

The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse

  • C. J. Rutty
  • D. R. Newell
  • J. R. F. Muindi
  • K. R. Harrap
Original Articles Pentamethylmelamine Pharmacokinetics
Received:
Accepted:

Summary

The pharmacokinetics of pentamethylmelamine (PMM) have been investigated in mouse (Balb C-, CBA/LAC, nude), rat (Wistar), and man. In all three species, PMM was extensively demethylated to N2,N2,N4,N6-tetramethylmelamine and N2,N4,N6-trimethylmelamine, although marked species differences in the rate of metabolism were observed. PMM metabolism was more rapid in the mouse (plasma t1/2 =<15 min) than in the rat (plasma t1/2=40 min), and slower in man (plasma t1/2=102 min) than in either mouse or rat. Furthermore, the peak plasma concentrations of N-methylolmelamines, intermediates generated during oxidative N-demethylation, were correspondingly higher in the mouse (563–773 μM) than in the rat (211 μM), whilst in man they were undetectable (<50 μM). In view of the highly cytotoxic nature of N-methylolmelamines, we conclude that these pharmacokinetic differences may be related to the antitumour effectiveness of PMM in mouse, rat, and man.

Keywords

Plasma Concentration Cancer Research Peak Plasma Species Difference Peak Plasma Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ames MM, Powis G (1979) Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorous gas-liquid chromatography. J Chromatogr 174:245Google Scholar
  2. 2.
    Ames MM, Powis G, Kovach JS, Eagan RT (1980) Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer Res 39:5016Google Scholar
  3. 3.
    Benvenuto A, Stewart DJ, Benjamin RS, Loo TL (1981) Pharmacology of pentamethylmelamine in humans Cancer Res 41:566Google Scholar
  4. 4.
    Borkovec AB, DeMilo AB (1967) Insect chemosterilants. V. Derivatives of melamine. J Med Chem 10:457Google Scholar
  5. 5.
    Casper ES, Gralla RJ, Lynch GR, Jones BR, Woodcock TM, Gordon C, Kelsen DP, Young CW (1981) Phase I and pharmacological studies of pentamethylmelamine administered by 24 hour infusion. Cancer Res 41:1402Google Scholar
  6. 6.
    Connors TA, Cumber AJ, Ross WCJ, Clarke SA, Mitchley BCV (1977) Regression of human lung tumour xenografts induced by water-soluble analogues of hexamethylmelamine. Cancer Treat Rep 61:927Google Scholar
  7. 7.
    Cumber AJ, Ross WCJ (1977) Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chem Biol Interact 17:349Google Scholar
  8. 8.
    DeMilo AB, Borkovec AB (1968) Insect chemosterilants. VII. Oxidative degradation of hexamethylmelamine. J Med Chem 11:961Google Scholar
  9. 9.
    D'Incalci M, Morazoni P, Pantarotto C (1979) Gas chromatographic determination of hexamethylmelamine in mouse plasma. Anal Biochem 99:441Google Scholar
  10. 10.
    Dutcher JS, Jones RB, Boyd MR (1980) A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies. Cancer Treat Rep 64:99Google Scholar
  11. 11.
    Echo DA, Chiuten DF, Whitacre M, Aisner J, Lichtenfield JL, Wiernik PH (1980) Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Cancer Treat Rep 64:1335Google Scholar
  12. 12.
    Gescher A, D'Incalci M, Fanelli R, Farina P (1980) N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine. Life Sci 26:147Google Scholar
  13. 13.
    Goldberg RS, Griffin JP, McSherry JW, Krakoff IH (1980) Phase I study of pentamethylmelamine. Cancer Treat Rep 64:1319Google Scholar
  14. 14.
    Goldin A, Venditti JM, Macdonald JS, Muggia FM, Henney JE, DeVita V (1981) Current results of the screening programme at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17:129Google Scholar
  15. 15.
    Hulshoff A, Neijt JP, Smulders CFA, Van Loenen AC, Pinedo HM (1980) Determination of hexamethylmelamine and metabolites in plasma or serum by gas-liquid chromatography with a nitrogen-sensitive detector. J Chromatogr 181:363Google Scholar
  16. 16.
    Ihde DC, Young RC, Cordes RS, Barlock AL, Dutcher JS, Jones RN, Boyd MR (1980) Phase I trial of pentamethylmelamine (PMM). Proc Am Assoc Cancer Res 21:143Google Scholar
  17. 17.
    Kaiser D, Thurston J, Dudley J, Schaefer F, Hechenbleckner I, Holm-Hansen D (1948) Cyanuric chloride derivatives. II. Substituted melamines. J Am Chem Soc 70:3726Google Scholar
  18. 18.
    Lomax NR, Narayanan VL (1979) Chemical structures of interest to the Division of Cancer Treatment. NCI, Washington, p 16 (Developmental Therapeutics Program)Google Scholar
  19. 19.
    Nash T (1953) The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 55:416Google Scholar
  20. 20.
    Newell DR, Hart LI, Harrap KR (1979) Estimation of chlorambucil, phenylacetic mustard and prednimustine in human plasma by high-performance liquid chromatography. J Chromatogr 164:114Google Scholar
  21. 21.
    Newell DR, Rutty CJ, Muindi JRF, Smith IE, Harrap KR (1980) Clinical and experimental studies with pentamethylmelamine (PMM). Br J Cancer 42:169Google Scholar
  22. 22.
    Rutty CJ, Connors TA (1977) In vitro studies with hexamethylmelamine. Biochem Pharmacol 26:2385Google Scholar
  23. 23.
    Rutty CJ, Abel G (1980) In vitro cytotoxicity of the methylmelamines. Chem Biol Interact 29:235Google Scholar
  24. 24.
    Rutty CJ, Connors TA, Nam NH, Thang DC, Hoellinger H (1978) In vivo studies with hexamethylmelamine. Eur J Cancer 14:713Google Scholar
  25. 25.
    Sampson J (1969) Non-linear least squares programme BMDX85. University of California Press, p 177 (University of California Publications in Automatic Computation, no. 3: BMD Biomedical Computing Programs X-series supplement)Google Scholar
  26. 26.
    Smith IE, Muindi JRF, Newell DR, Merai K, Rutty CJ, Wilman DEV, Taylor RE (1980) Pentamethylmelamine (PMM): Phase I and pharmacokinetic studies. Proc Am Assoc Cancer Res 21:136Google Scholar
  27. 27.
    Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton Ill, p 71Google Scholar
  28. 28.
    Worzalla JF, Johnson BM, Ramirez G, Bryan GT (1973) N-Demethylation of the antineoplastic agent hexamethylmelamine by rats and man. Cancer Res 33:2810Google Scholar
  29. 29.
    Worzalla JF, Kaiman BD, Johnson BM, Ramirez G, Bryan G (1974) Metabolism of hexamethylmelamine-ring-14C in rats and man. Cancer Res 34:2669Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • C. J. Rutty
    • 1
  • D. R. Newell
    • 1
  • J. R. F. Muindi
    • 1
  • K. R. Harrap
    • 1
  1. 1.Department of Biochemical PharmacologyInstitute of Cancer ResearchSuttonGreat Britain

Personalised recommendations